Zidebactam,formerly described as WCK5107,was reseached and developed by an Indian company Wockhardt.Zidebactam is a novel non-β-lactam bicyclo-acyl hydrazide that has a dual mechanism of action.In 2022,a clinical application for wck-5222 was submitted in China by Wockhardt,and the approval was granted for complicated urinary tract infections in adults,including acute pyelonephritis.This review focuses on its drug action mechanism,preclinical pharmacology,and pharmacokinetics,which was extracting the latest preclinical and clinical research progress of zidabatam from existing literature,and expect to provide information for pharmaceutical workers.
zidebactamcefepimemechanism of actionpharmacologypharmacokinetics
万方数据
维普
